Search Result
Results for "
Intravenously
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B2068
-
-
-
- HY-P4154
-
|
ALM-488
|
Fluorescent Dye
|
Neurological Disease
Cancer
|
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
-
- HY-117979
-
|
Alfadolone
|
Others
|
Cancer
|
|
Alphadolone is an intravenous agent that can suppress or relieve pain. Alphadolone causes general anaesthesia .
|
-
-
- HY-148155
-
-
-
- HY-136476A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Mn(II) protoporphyrin IX is a potential intravenous paramagnetic magnetic resonance contrast agent. Mn(II) protoporphyrin IX maintains strong paramagnetic properties .
|
-
-
- HY-144773A
-
|
HR1405–01
|
COX
|
Inflammation/Immunology
|
|
Loxoprofenol-SRS tromethamine (HR1405-01), an active metabolite of Loxoprofen, is a Safe intravenous non-steroidal anti-inflammatory drug (NSAID) with superior anti-inflammatory and analgesic activities .
|
-
-
- HY-N10225
-
|
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration .
|
-
-
- HY-B1657
-
|
|
Others
|
Neurological Disease
|
|
Fosphenytoin is a phosphate ester proagent developed as an alternative to intravenous phenytoin for acute intervention of seizures. Fosphenytoin has advantages including more convenient and rapid intravenous administration, availability for intramuscular injection, and low potential for adverse local reactions at injection sites .
|
-
-
- HY-P3854
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
GR 83074 is a potent and selective NK-2 (Neurokinin Receptor) antagonist with a pKB of 8.23. GR 83074 is inactive as an NK-3 antagonist and exhibits a 340-fold NK-2/NK-1 selectivity .
|
-
-
- HY-118683
-
|
|
Others
|
Others
|
|
KR-31378 is a neuroprotectant with dose-dependent pharmacokinetic properties and relevant activity in rats. After intravenous and oral administration of KR-31378 in rats, its pharmacokinetic parameters showed dose-dependent changes, such as decreased clearance with increasing doses, good oral absorption, and comparable AUCs for intravenous and oral administration at different doses.
|
-
-
- HY-B1297
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Ceforanide is a second generation cephalosporin administered intravenously or intramuscularly. Ceforanide has a spectrum of in vitro antibacterial activity .
|
-
-
- HY-129804
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Ceforanide lysine is a second generation cephalosporin administered intravenously or intramuscularly. Ceforanide lysine has a spectrum of in vitro antibacterial activity .
|
-
-
- HY-W181626A
-
|
DU 21445 hydrochloride
|
5-HT Receptor
|
Cardiovascular Disease
|
|
Tiprenolol hydrochloride is a β-adrenoceptor blocker. Tiprenolol hydrochloride abolished ventricular arrhythmias induced by intravenous epinephrine in dogs receiving halothane inhalation .
|
-
-
- HY-144773
-
|
|
Drug Metabolite
|
Inflammation/Immunology
|
|
Loxoprofenol-SRS, an active metabolite of Loxoprofen, is a new intravenous NSAID. Loxoprofenol-SRS exhibits significantly stronger anti-inflammatory and analgesic activities .
|
-
-
- HY-135578
-
|
|
Parasite
|
Infection
|
|
Artelinic acid, a derivative of Artemisinin, is an antimalarial agent for the treatment of multidrug resistant strains of Plasmodium falciparum. Artelinic acid can be administered by various routes of administration, including intravenous, intramuscular and oral routes .
|
-
-
- HY-B1297R
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Ceforanide (Standard) is the analytical standard of Ceforanide. This product is intended for research and analytical applications. Ceforanide is a second generation cephalosporin administered intravenously or intramuscularly. Ceforanide has a spectrum of in vitro antibacterial activity .
|
-
-
- HY-P5889
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .
|
-
-
- HY-N6910
-
|
|
Others
|
Metabolic Disease
|
|
Pseudolaric Acid C2, a diterpenoid isolated from Pseudolarix kaempferi, is identified as the specific metabolite of Pseudolaric acid B in plasma, urine, bile and feces after both oral and intravenous administration to rats .
|
-
-
- HY-121573
-
|
|
Biochemical Assay Reagents
|
Cardiovascular Disease
|
|
α-Acetyldigoxin can be used in heart failure related research and is orally available. The bioavailability of α-Acetyldigoxin is lower than that of β-Acetyldigoxin when administered orally and intravenously .
|
-
-
- HY-11021
-
|
PRT060128
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects .
|
-
-
- HY-105236
-
|
(Rac)-CI-977 free base
|
Others
|
Neurological Disease
|
|
(Rac)-Enadoline ((Rac)-CI-977 free base) is a selective K-opioid receptor agonist that stereoselectively antagonizes clonic seizures induced by slow intravenous injection of N-methyl-DL-aspartate in mice .
|
-
-
- HY-B1300A
-
|
|
Others
|
Others
|
|
Pharmacokinetic studies of Cefonicid have shown that high blood concentrations can be achieved rapidly after intravenous and intramuscular injection, and that concomitant use of albendazole prolongs its half-life in the body and reduces the rate of renal excretion .
|
-
-
- HY-114536
-
|
NSC 104800
|
Others
|
Others
|
|
Mitolactol (NSC 104800) is an angiotensin converting enzyme (ACE) inhibitor with the activity of inhibiting ACE (IC50 of 1.4×10?? M) and inhibiting the pressor response of angiotensin I when administered intravenously at 0.3 mg/kg in rats.
|
-
-
- HY-105919
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
|
-
-
- HY-B1300B
-
|
|
Others
|
Others
|
|
Pharmacokinetic studies of Cefonicid monosodium have shown that high blood concentrations can be achieved rapidly after intravenous and intramuscular injection, and that concomitant use of albendazole prolongs its half-life in the body and reduces the rate of renal excretion .
|
-
-
- HY-N10226
-
|
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Thielavin B is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin B effectively influences the prostaglandin E2 synthesis from the endoperoxide. Thielavin B is significantly effective on carrageenan-induced oedema of rats when administered intravenously .
|
-
-
- HY-163684
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Zoracopan is a selective complement factor D (CFD) inhibitor. When administered systemically (orally or intravenously), Zoracopan accumulates and is sustained-released in ocular tissues, primarily in the choroid-retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB) .
|
-
-
- HY-121045
-
|
KO 1366
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Bunitrolol is a beta-adrenergic antagonist. Bunitrolol has intrinsic sympathomimetic activity. Bunitrolol can be used for the research of ischemic myocardium .
|
-
-
- HY-100435
-
|
MCB-3837; DNV3837
|
Bacterial
|
Infection
|
|
Oxaquin (MCB-3837) is a injectable proagent that is rapidly converted to the active substance MCB3681 in vivo following intravenous (i.v.) administration, active against Gram-positive bacterial species. Oxaquin (MCB-3837) itself has no antimicrobial effects .
|
-
-
- HY-109106A
-
|
|
CaSR
|
Endocrinology
|
|
Upacicalcet sodium is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell membrane calcium-sensing receptors. Upacicalcet can be used for researching the disease of secondary hyperparathyroidism (SHPT) .
|
-
-
- HY-109106
-
|
|
CaSR
|
Endocrinology
|
|
Upacicalcet is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell membrane calcium-sensing receptors. Upacicalcet can be used for researching the disease of secondary hyperparathyroidism (SHPT) .
|
-
-
- HY-B0302
-
|
Etidronate; HEDPA; HEDP
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
|
-
-
- HY-B2203
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Monocalcium glycerophosphate is an inhibitor of intestinal alkaline phosphatase F3, and it has anti-cavity properties. Monocalcium glycerophosphate is a source of calcium and phosphorus in total parenteral nutrition solutions, helps prevent the mineralization and development of bones from intravenous nutrition, and maintains the integrity of the intestinal epithelium .
|
-
-
- HY-109106B
-
|
|
CaSR
|
Endocrinology
|
|
(Rac)-Upacicalcet is the racemate of Upacicalcet.Upacicalcet is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell membrane calcium-sensing receptors. Upacicalcet can be used for researching the disease of secondary hyperparathyroidism (SHPT) .
|
-
-
- HY-122529
-
|
|
Bacterial
|
Infection
|
|
Almurtide (nor-MDP), a muramyl dipeptide derivative with anti-inflammatory and anti-tumor activity. Almurtide also shows protective effects against intraperitoneal Pseudomonas aeruginosa infection or intravenously Candida albicans infection in mice. Almurtide also inhibits the carcinogenic Friend leukemia virus .
|
-
-
- HY-14658B
-
-
-
- HY-106258
-
|
OHM 11638; BAX-ACC 1638; MOT 288
|
Motilin Receptor
|
Metabolic Disease
|
|
OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a pKd of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents .
|
-
-
- HY-B0302A
-
|
Etidronate disodium; HEDPA disodium; HEDP disodium
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
|
-
-
- HY-105215
-
|
|
Neurokinin Receptor
|
Inflammation/Immunology
|
|
FK888 is a potent, selective, and high affinity dipeptide NK1 receptor antagonist. FK888 displaces [3H]-SP binding with a Ki value of 0.69 nM and 0.45 microM. FK888 also inhibits SP-induced airway oedema in guinea-pig after both intravenous and oral administration .
|
-
-
- HY-19638
-
|
AR-C69931MX
|
P2Y Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .
|
-
-
- HY-W071746
-
|
Linoelaidic acid
|
Endogenous Metabolite
Parasite
Apoptosis
|
Infection
Inflammation/Immunology
|
|
Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections .
|
-
-
- HY-106572A
-
|
|
Bacterial
|
Infection
|
|
Cefbuperazone sodium is an antibacterial agent that demonstrates significant activity against bacterial infections. Cefbuperazone sodium exhibits a linear pharmacokinetic profile, allowing for effective dosage determination in clinical settings. Cefbuperazone sodium reaches peak concentrations in human plasma following intravenous infusion, indicating its rapid absorption and distribution. Cefbuperazone sodium is primarily excreted unchanged in urine, highlighting its efficiency in renal elimination.
|
-
-
- HY-19638A
-
|
AR-C69931MX tetrasodium
|
P2Y Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
|
-
-
- HY-130522
-
|
6β-PGI1
|
Others
|
Others
|
|
6β-Prostaglandin I1 (6β-PGI1) is an analog of prostaglandin I2 (PGI2) that is resistant to hydrolysis in aqueous solutions. 6β-Prostaglandin I1 can reduce gastric acid secretion with an ID50 (dose causing 50% inhibition) of approximately 3.0 μg/kg/min (intravenous injection) .
|
-
-
- HY-137500
-
|
|
Liposome
|
Neurological Disease
|
|
NT1-014B is a potent NT1-lipidoid encapsulated AmB (amphotericin B). NT1-014B dopes the NT-lipidoids into BBB-impermeable lipid nanoparticles (LNPs) gave the LNPs the ability to cross the BBB. NT1-014B enhances brain delivery through intravenous injection .
|
-
-
- HY-118350
-
|
|
Others
|
Neurological Disease
|
|
FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester series compound that can inhibit the contraction of the detrusor muscle of guinea pig bladder (IC50=3.3 μg/mL). After intravenous injection of FR 75513 into anesthetized rats, it also showed strong inhibitory activity on the detrusor contraction (ID50=0.04 mg/kg).
|
-
-
- HY-118185
-
|
|
Others
|
Others
|
|
SQ 31844 is a novel renin inhibitor belonging to the imidazolidinol class. This compound, which contains an imidazole ring in its active site binding group, has potent in vitro inhibition of primate renin, but not rat, pig, or dog renin. In conscious, sodium-deprived cynomolgus monkeys, both compounds produced dose-related inhibition of plasma renin activity (PRA) over a dose range of 0.001 to 1.0 μmol/kg, administered intravenously, with complete inhibition observed at the highest dose. However, a reduction in blood pressure was only observed when 10 μmol/kg was administered intravenously or by infusion. In sodium-replete monkeys, SQ 30774 inhibited the increase in arterial blood pressure and PRA following administration of exogenous monkey renin. When the compounds were administered orally at 50 μmol/kg, only SQ 31844 significantly inhibited PRA (80%). In summary, the imidazolidinol renin inhibitors have potent inhibitory effects on renin in vitro and inhibit PRA and reduce arterial blood pressure in vivo.
|
-
-
- HY-B0302AR
-
|
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Etidronic acid (disodium) (Standard) is the analytical standard of Etidronic acid (disodium). This product is intended for research and analytical applications. Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
|
-
-
- HY-15346
-
Copanlisib
Maximum Cited Publications
25 Publications Verification
BAY 80-6946
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
|
-
-
- HY-14658A
-
-
- HY-15346A
-
|
BAY 80-6946 dihydrochloride
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .
|
-
- HY-109513
-
Ioxilan
1 Publications Verification
|
Biochemical Assay Reagents
|
Others
|
|
Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs .
|
-
- HY-15346R
-
|
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib (Standard) is the analytical standard of Copanlisib. This product is intended for research and analytical applications. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
|
-
- HY-109513R
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Ioxilan (Standard) is the analytical standard of Ioxilan. This product is intended for research and analytical applications. Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs .
|
-
- HY-112624C
-
|
|
Biochemical Assay Reagents
Endogenous Metabolite
|
Others
|
|
Dextran (MW 40000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.
|
-
- HY-112624B
-
|
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
Biochemical Assay Reagents
|
Others
|
|
Dextran T70 (MW 70,000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.
|
-
- HY-106720C
-
|
(+)-YM 09538
|
Others
|
Others
|
|
(+)-Amosulalol ((+)-YM 09538) is an α,β-blocker with pharmacokinetic and metabolic activities in mice. In mice, the plasma concentration of (+)-Amosulalol decreased in a biphasic manner after intravenous injection. The time to reach the maximum plasma concentration after oral administration was 0.25h, and then decreased. The systemic bioavailability was 38.7%, and it was mainly excreted through urine. Multiple metabolites were detected in urine, and a new metabolite amosulalol carbamoyl glucuronide was found in bile samples.
|
-
- HY-106720B
-
|
(-)-YM 09538
|
Others
|
Others
|
|
(-)-Amosulalol ((-)-YM 09538) is an α,β-blocker with pharmacokinetic and metabolic activities in mice. In mice, the plasma concentration of (-)-Amosulalol decreased in a biphasic manner after intravenous injection. The time to reach the maximum plasma concentration after oral administration was 0.25h, and then decreased. The systemic bioavailability was 38.7%, and it was mainly excreted through urine. Multiple metabolites were detected in urine, and a new metabolite amosulalol carbamoyl glucuronide was found in bile samples.
|
-
- HY-12976
-
|
|
G Protein-coupled Receptor Kinase (GRK)
|
Metabolic Disease
|
|
DS-1558 is an orally active small molecule G protein-coupled receptor 40 agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes .
|
-
- HY-14795
-
|
ZT-1
|
|
Neurological Disease
|
|
Mimopezil (ZT-1) is an cholinesterase (ChE) inhibitor that rapidly degrades into the active metabolite Huperzine A (HY-17388) in water or aqueous organic solvents. After oral administration, Mimopezil is rapidly absorbed but has low bioavailability (0.37%) in rats. However, after metabolism, it is converted into Huperzine A, which accumulates in the blood and exhibits strong activity. Following intravenous administration, Mimopezil reaches higher blood concentrations and is also rapidly metabolized into Huperzine A .
|
-
- HY-103019E
-
|
BAY-1251152; VIP152
|
Others
|
Others
|
|
Enitociclib (VIP152; BAY-1251152) is a selective CDK9 inhibitor. Known for its unique benzyl sulfoxide moiety, VIP152 has demonstrated promising efficacy and tolerability both in vitro and in vivo, including in mouse and rat xenograft models via weekly intravenous infusions Highly effective and well tolerated. VIP152 shows promising long-term single-agent inhibitory activity against double-click refractory diffuse large B-cell lymphoma .
|
-
- HY-19336
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BAZ2-ICR is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains. BAZ2-ICR is an epigenetic chemical probe .
|
-
- HY-121772
-
|
(+)-Actinopyrone A; SS 1538A
|
Others
|
Infection
|
|
Actinopyrone A is a pyrone isolated from S. pactum with diverse biological activities. It has selective and potent antimicrobial activity against H. pylori (MIC=0.1 ng/mL) with no activity against other Gram-negative bacteria including E. coli, K. pneumoniae, P. aeruginosa, and B. fragilis. Actinopyrone A also mildly inhibits growth of Gram-positive bacteria and dermatophytes with MIC values ranging from 1 Intravenous administration of actinopyrone A (30 μg/kg) increases coronary blood flow in dogs by 196.2%.
|
-
- HY-115400
-
1V209
3 Publications Verification
TLR7 agonist T7
|
Toll-like Receptor (TLR)
|
Cancer
|
|
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity .
|
-
- HY-158014
-
|
|
Dopamine Transporter
|
Neurological Disease
|
|
JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .
|
-
- HY-B2227B
-
|
Lactic acid sodium
|
Bacterial
|
Metabolic Disease
Cancer
|
|
Lactate (Lactic acid) sodium is the product of glycogenolysis and glycolysis . Lactate (Lactic acid) sodium is an organic salt that is mainly used as a buffer and pH adjuster for injection solutions. Lactate sodium can be metabolized by the body into sodium bicarbonate, which in turn acts to increase the pH of the blood. Lactate sodium is used to improve metabolic acidosis and hypovolemic states. In terms of pharmaceutical preparations, Lactate sodium is often used in combination with sodium chloride, glucose, etc. to form normal saline or compound liquid intravenous injection . Lactate sodium also has antimicrobial activity, which can be used as a food preservative .
|
-
- HY-14915
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
Bedoradrine is a highly selective β2-adrenergic agonist with activity in suppressing asthma and chronic obstructive pulmonary disease (COPD). Bedoradrine is administered by intravenous infusion and is specifically indicated for the suppression of acute asthma attacks. Bedoradrine has shown good safety and preliminary efficacy in clinical trials, especially in patients with stable moderate to severe asthma. The results of Bedoradrine studies have shown that it can provide clinical benefits without increasing clinical risks, especially for patients who are unable to use inhalation or nebulization suppression .
|
-
- HY-P0093
-
|
Cholecystokinin octapeptide; CCK-8; SQ19844
|
Cholecystokinin Receptor
Apoptosis
PI3K
Akt
|
Infection
Cancer
|
|
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK .
|
-
- HY-P0093A
-
|
Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium
|
Cholecystokinin Receptor
Apoptosis
PI3K
Akt
|
Infection
Cancer
|
|
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK .
|
-
- HY-B2227BR
-
|
|
Bacterial
|
Metabolic Disease
Cancer
|
|
Lactate (sodium) (Standard) is the analytical standard of Lactate (sodium). This product is intended for research and analytical applications. Lactate (Lactic acid) sodium is the product of glycogenolysis and glycolysis . Lactate (Lactic acid) sodium is an organic salt that is mainly used as a buffer and pH adjuster for injection solutions. Lactate sodium can be metabolized by the body into sodium bicarbonate, which in turn acts to increase the pH of the blood. Lactate sodium is used to improve metabolic acidosis and hypovolemic states. In terms of pharmaceutical preparations, Lactate sodium is often used in combination with sodium chloride, glucose, etc. to form normal saline or compound liquid intravenous injection [4] . Lactate sodium also has antimicrobial activity, which can be used as a food preservative .
|
-
- HY-117380
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
SB 235375 is a potent and selective antagonist of the human neurokinin-3 (hNK-3) receptor designed by optimizing the structure of 2-phenyl-4-quinolinecarboxylic acid amide. SB 235375 displays high affinity for the hNK-3 receptor, with significantly higher binding affinities than hNK-2 and hNK-1 receptors. In vitro studies demonstrated its ability to block NK-3 receptor-mediated contraction and calcium mobilization, while in vivo, SB 223412 demonstrated oral and intravenous activity against NK-3 receptor-driven responses in animal models .
|
-
- HY-15074
-
|
NS-1209
|
iGluR
|
Neurological Disease
|
|
SPD-502 is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity .
|
-
- HY-15076
-
|
NS-1209 sodium
|
iGluR
|
Neurological Disease
|
|
SPD-502 sodium is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 sodium effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 sodium may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity .
|
-
- HY-15007
-
|
|
Oxytocin Receptor
|
Endocrinology
|
|
L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists .
|
-
- HY-134160
-
|
5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione; 5-Fluorodihydrouracil
|
Others
|
Cancer
|
|
5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC50=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.
|
-
- HY-163345
-
|
|
5-HT Receptor
|
Neurological Disease
|
5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a Ki of 67 nM, the IC50 values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment .
Pharmacokinetic Analysis ICR Male Mice
药代动力学分析
| Plasma |
Intravenous Administration |
Intraperitoneal Administration |
| Tmax (h) |
0.08 |
0.25 |
| T1/2 (h) |
0.77 |
1.06 |
| Cmax (ng/mL) |
33.07 |
156.44 |
| AUClast (ng·h/mL) |
28.31 |
143.27 |
| CL (L/h/kg) |
41.61 |
- |
| Vss (L/kg) |
32.43 |
- |
| MRT (h) |
0.79 |
0.93 |
| F (%) |
50.60 |
|
|
-
- HY-117811
-
|
L-680574
|
Others
|
Others
|
|
(R,R)-MK 287 is a tetrahydrofuran derivative that effectively inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with K1 values of 6.1 ± 1.5, 3.2 ± 0.7, and 5.49 ± 2.3 nM, respectively. The inhibition is stereospecific and competitive. Its racemate, L-668,750, is less potent, and its enantiomer, L-680574, is only 1/20 as potent as MK 287. MK 287 inhibits the binding of [3H]C18-PAF to human PMN membranes, reducing the affinity of the radioligand without changing the number of receptor sites. The binding of other radioligands (e.g., LTB4, LTC4, C5a, FMLP) to their specific receptors is unchanged at 1-10 microM MK 287. [3H]MK 287 binds to human platelet and PMN membranes with KD values of 2.1 ± 0.6 and 2.9 ± 1.2 nM. When tested on isolated human cells, MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50 = 56 ± 38 nM or ED50 = 1.5 ± 0.5 nM for gel-filtered platelets) and elastase release from PMNs (ED50 = 4.4 ± 2.6 nM). In vivo studies, MK 287 inhibited PAF-induced lethality in mice (ED50 = 0.8 mg/kg oral) and PAF-induced bronchospasm in guinea pigs (ED50 = 0.18 mg/kg intraduodenally and 0.19 mg/kg intravenously). The inhibition of PAF-induced bronchospasm was accompanied by a rightward shift in the concentration-response curve for PAF-induced platelet aggregation measured in vitro.
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-137500
-
|
|
Drug Delivery
|
|
NT1-014B is a potent NT1-lipidoid encapsulated AmB (amphotericin B). NT1-014B dopes the NT-lipidoids into BBB-impermeable lipid nanoparticles (LNPs) gave the LNPs the ability to cross the BBB. NT1-014B enhances brain delivery through intravenous injection .
|
-
- HY-112624C
-
|
|
Thickeners
|
|
Dextran (MW 40000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.
|
-
- HY-112624B
-
|
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
Drug Delivery
Thickeners
|
|
Dextran T70 (MW 70,000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4154
-
|
ALM-488
|
Fluorescent Dye
|
Neurological Disease
Cancer
|
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
- HY-P0093
-
|
Cholecystokinin octapeptide; CCK-8; SQ19844
|
Cholecystokinin Receptor
Apoptosis
PI3K
Akt
|
Infection
Cancer
|
|
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK .
|
-
- HY-P0093A
-
|
Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium
|
Cholecystokinin Receptor
Apoptosis
PI3K
Akt
|
Infection
Cancer
|
|
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK .
|
-
- HY-P3854
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
GR 83074 is a potent and selective NK-2 (Neurokinin Receptor) antagonist with a pKB of 8.23. GR 83074 is inactive as an NK-3 antagonist and exhibits a 340-fold NK-2/NK-1 selectivity .
|
-
- HY-P5889
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .
|
-
- HY-106258
-
|
OHM 11638; BAX-ACC 1638; MOT 288
|
Motilin Receptor
|
Metabolic Disease
|
|
OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a pKd of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
|
Classification |
-
- HY-137500
-
|
|
|
Cationic Lipids
|
|
NT1-014B is a potent NT1-lipidoid encapsulated AmB (amphotericin B). NT1-014B dopes the NT-lipidoids into BBB-impermeable lipid nanoparticles (LNPs) gave the LNPs the ability to cross the BBB. NT1-014B enhances brain delivery through intravenous injection .
|
-
- HY-112624B
-
|
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
|
Polymers
|
|
Dextran T70 (MW 70,000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
